One of PrIMAVeRa ’s early outputs was included within the European Commission’s online Innovation Radar platform. 

The project achieved a significant project milestone by completing the mid-term review, presenting project progress for a panel of external experts during a virtual meeting held on 02 April.

Partners celebrate the newest project manuscript. The scope expanded to include monoclonal antibodies as a control measure and investigate the impact of secondary infections.

The project achieved a significant project milestone by completing the mid-term review, presenting project progress for a panel of external experts during a virtual meeting held on 02 April.

The meeting was filled with intensive scientific discussions centred around identifying strategies to best refine and expand the mathematical models that will power the platform being developed.

The European Vaccine Initiative, in cooperation with University Medical Center Utrecht and GSK Vaccines, has produced an informative...

PrIMAVeRa proudly took part in the AMR Accelerator Cross-Project Meeting 2025 in Basel

A new manuscript describing the sharing and re-use of data, along with challenges encountered and potential solutions, was just published.

December 2024 PrIMAVeRa is proud to be part of the IMI Antimicrobial Resistance (AMR) Accelerator, an Innovative Medicines Initiative...

A new manuscript focused on data needs for the development of vaccines and monoclonal antibodies (mAbs) to effectively address AMR was...

The third annual meeting of the PrIMAVeRa project took place on 07-08 November 2024 in Seville, Spain. Approximately 35 participants...

The PrIMAVeRa project, a public-private partnership supported by the European Federation of Pharmaceutical Industries and Associations...

Antibiotic resistance is a global public health threat. Modern health systems rely on antibiotics to prevent and treat infections, and...

Activities continue in the PrIMAVeRa project, with the latest result being the publication of a new manuscript titled “Using contact...

Divided into two rounds during June, Consortium partners presented year two progress to SAC.

The team shared challenges & solutions for data-sharing & re-use, and expert consensus on priorities for vaccine/mAb R&D and implementation.

The Cross-Project Meeting gathered nearly 40 participants representing 9 IHI-funded projects from the AMR Accelerator, in Basel, Switzerland

The PrIMAVeRa project proudly announces the simultaneous publication of four informative systematic reviews.

The meeting enabled dynamic panel discussions covering the burden of AMR, and model development and data access.

The PrIMAVeRa project announces the appointment of the Scientific Advisory Committee (SAC).